Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Erythropoietin Found Involved in Origin and Metastasis of Cancer

By BiotechDaily International staff writers
Posted on 19 Dec 2011
Researchers have demonstrated that a platelet-derived growth factor-BB (PDGF-BB) and the blood protein erythropoietin (EPO) are involved in the development of cancerous tumors and that they combine to help the tumors flourish in the body. These new preclinical findings offer new potential for suppressing tumor growth and bypassing difficulties of resistance that exist with many drugs in current use.

The study’s findings were published online December 4, 2011, in the journal Nature Medicine. Angiogenesis is the formation of new blood vessels from preexisting ones, and is one of the most important research fields in the treatment of such diverse disorders such as cancer, metastases, obesity, heart disease, stroke, diabetes, and chronic inflammation. The process is also important in healthy individuals for wound healing, the menstrual cycle, and other normal processes. Prof. Yihai Cao and his coworkers from the Karolinska Institute (Stockholm, Sweden) are examining the angiogenesis process and its ties to cancer and other disorders, and in the present study, they revealed the critical role played by growth factor PDGF-BB.

“It’s a member of the PDGF family and significantly contributes to blood vessel development, which is one of the characteristic signs of cancer,” said Prof. Yihai Cao. Our preclinical findings suggest that PDGF-BB causes systemic effects in the body, which is to say that rather than being active locally it goes into the blood and interferes with the function of several organs so that the entire body is affected.”

The studies were conducted on lab mice, and in this study, the investigators were able to demonstrate that when the growth factor PDGF-BB binds to its receptors, it stimulates the blood protein EPO, which then regulates the production of red blood cells that provide more oxygen for tumor growth and metastasis. “EPO has several functions,” remarked Prof. Cao. “It produces more blood and stimulates angiogenesis, and we have revealed the underlying mechanism. It also stimulates tumor angiogenesis by directly stimulating the proliferation, migration, and growth of endothelial cells and their ability to form the so-called epithelial tube. PDGF-BB promotes the stimulation of extramedullary hematopoiesis, enlargement of the liver and spleen, which increases oxygen perfusion and protection against anemia.”

The introduction of PDGF-BB in mice therefore increases erythropoietin production and the hematopoietic parameters. Moreover, EPO may directly act on tumor cells to stimulate their growth and metastasis. “We believe that the increase in EPO might be responsible for tumoral resistance to antiangiogenetic drugs, which only target PDGF ligands. The combination of drugs targeted at both PDGF and EPO has potential superior therapeutic benefits,” stated Prof. Yihai Cao, adding that they will continue to research mouse models and assess opportunities for clinical studies on patients.

Prof. Yihai Cao is also affiliated to Linköping University (Linköping, Sweden). Researchers from Karolinska Institute, Linköping University, and the University of Toyama (Toyama, Japan) contributed to the study.

Related Links:

Karolinska Institute
Linköping University
University of Toyama




RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.